Comparing Intensive and Standard Training for Human Insulin Inhalation Powder (HIIP)
Phase 2
Completed
- Conditions
- Diabetes Mellitus, Type 2
- Interventions
- Drug: LY041001 (HIIP)
- Registration Number
- NCT00099515
- Lead Sponsor
- Eli Lilly and Company
- Brief Summary
The purpose of this study is to compare intensive and standard training for human insulin inhalation powder in patients with type 2 diabetes.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 97
Inclusion Criteria
- Type 2 diabetes for at least 12 months
- Age 18 or older.
- Taking at least 1 oral antihyperglycemic medication.
- Have an HbA1C between 7.5 and 12.
- Be a nonsmoker
Exclusion Criteria
- Body Mass Index (BMI) greater than 40.
- Have frequent episodes of severe hypoglycemia.
- Have advanced autonomic neuropathy.
- Have history of asthma.
- Have chronic obstructive pulmonary disease (COPD).
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description A LY041001 (HIIP) - B LY041001 (HIIP) -
- Primary Outcome Measures
Name Time Method Hypothesis that std training for HIIP system is noninferior to intensive training by 1.2 mmol/L with respect to overall 2-hr postprandial glucose excursion of (SMBG) in type 2 diabetes patients that have been on preprandial trmt with HIIP 4 weeks
- Secondary Outcome Measures
Name Time Method Assess the suitability of the HIIP delivery system for type 2 diabetes patients 4 weeks Compare the SMBG profiles of preprandial HIIP administration with standard training and with intensive training Assess patient compliance with the HIIP delivery system Directions for Use (DFU) provided by the Sponsor with and without intensive training 4 weeks Compare the test meal blood glucose profiles of preprandial HIIP administration with standard training and with intensive training 4 weeks
Trial Locations
- Locations (1)
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
🇿🇦George, South Africa
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.🇿🇦George, South Africa